• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Springleaf Therapeutics

edit

SpringLeaf Therapeutics is creating innovative therapeutic modalities to address serious disease and elevate the quality of care for patients. SpringLeaf’s technology is based on convergent science and is designed to enable and differentiate therapeutics. SpringLeaf was founded based on breakthrough science at MIT and is backed by leading investors including Flybridge Capital Partners and North Bridge Venture Partners.

Milestones

edit

• 
  Springleaf Therapeutics added Pieter Muntendam as President and CEO.
  Posted 9/19/12 at 8:11pm
• 
  Springleaf Therapeutics received $4M in Series B funding. (7/8/11)
  Posted 7/8/11 at 7:08pm via springleaftx.com
• 
  Springleaf Therapeutics received $15M in Series B funding. (5/12/11)
  Posted 5/12/11 at 12:28am via masshightech.com

Videos

Screenshots

edit

Above: Springleaf Therapeutics
Uploaded: 5/12/11

Sources

1. SpringLeaf Therapeutics raises $15M Series B round (masshightech.com) [edit]
2. SpringLeaf Therapeutics Announces Second Close of Series B Financing (springleaftx.com) [edit]